author-photo

Marlisa Anderson

5

Papers

11

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)